Effects of 6-12 months of esomeprazole treatment on the gastric mucosa

American Journal of Gastroenterology

Volumn 98, Issue 6, 2003, Pages 1257-1265

  Genta, Robert M ^a   Rindi, Guido ^b   Fiocca, Roberto ^b   Magner, David J ^b   D'Amico, Donald ^b   Levine, Douglas S ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; GASTRIN; PLACEBO;

ARTICLE; ATROPHIC GASTRITIS; BACTERIUM DETECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENTEROCHROMAFFIN CELL; GASTRIN BLOOD LEVEL; GASTRITIS; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA;

EID: 0037973525     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00268-5     Document Type: Article

References (53)

1. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994;69:867-76.
2. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11(suppl B):66-73B.
3. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995;36:492-8.
4. Richardson CT, Bailey BA, Walsh JH, et al. The effect of an H2-receptor antagonist on food-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcers. Comparison with an anticholinergic drug. J Clin Invest 1975;55:536-42.
5. Allen JM, Adrian TE, Webster J, et al. Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepato-Gastroenterology 1984;31:44-6.
6. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twentyfour-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.
7. Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 1991;180(suppl):179-91.
8. Mattsson H, Havu N, Brautigam J, et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like-cell carcinoids in the rat. Gastroenterology 1991;100:311-9.
9. Havu N, Mattsson H, Ekman L, et al. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long term administration of ranitidine. Digestion 1990;45:189-95.
10. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication [see comments]. N Engl J Med 1996;334:1018-22.
11. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa [see comments]. Gastroenterology 2000;118:661-9.
12. Laine L, Ahnen D, McClain C, et al. Review article: Potential gastrointestinal effects of long term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.
13. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 1999;117:319-26.
14. Singh P, Velasco M, Given R, et al. Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. Gastroenterology 2000;119:162-71.
15. Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: A prospective study. Gastroenterology 1998;115:275-80.
16. Begos DG, Modlin IM. Gastrin and colon cancer. Clarifying the controversy. J Clin Gastroenterol 1994;18:189-93.
17. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7.
18. Röhss K, Claar-Nilsson C, Lundin C, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000;118:A-20.
19. Röhss K, Lundin C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg. Am J Gastroenterol 2000;95:2432-3.
20. Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000;118:A-22.
21. Wilder-Smith C, Röhss K, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut 2000;47:A-63.
22. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
23. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
24. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
25. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
26. Vakil N, Shaker R, Johnson DA. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-35.
27. Maton P, Vakil NB, Levine JG, Hwang C, et al. The safety and efficacy of long term esomeprazole therapy in patients with healed erosive esophagitis. Drug Safety 2001;24:625-35.
28. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
29. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: A new stain. Hum Pathol 1994;25:221-6.
30. Genta R. Defining atrophic gastritis and grading gastric atrophy: New challenges beyond the Sydney System. Dordrecht: Kluwer Academic Publishers, 1998.
31. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
32. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988;41:185-200.
33. Solcia E, Fiocca R, Villani L, et al. Hyperplastic, dysplastic, and neoplastic enterochromafin-like cell proliferation of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995;19(suppl 1):S1-7.
34. Genta R, Rugge M. Gastric precancerous lesions: Heading for an international consensus. Gut 1999;45(suppl 1):15-8.
35. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992;102:720-7.
36. Fiocca R, Villani L, Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: A morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 1992;420:489-98.
37. Correa P, Haenszel W, Cuello C, Tannenbaum S, et al. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.
38. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res 1990;50:4737-40.
39. Kekki M, Villako K. Dynamic behaviour of gastritis in various populations and subpopulations. Ann Clin Res 1981;13:119-22.
40. Katelaris PH, Seow F, Lin BP, et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993;34:1032-7.
41. Ihamaki T, Kekki M, Sipponen P, et al. The sequelae and course of chronic gastritis during a 30- to 34-year bioptic follow-up study. Scand J Gastroenterol 1985;20:485-91.
42. Fontham ET, Ruiz B, Perez A, et al. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995;90:1094-101.
43. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long term treatment with omeprazole for refractory reflux esophagitis. Efficacy and safety [see comments]. Ann Intern Med 1994;121:161-7.
44. Brunner G, Harke U. Long term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994;8:59-64.
45. Delle Fave G, Helander H, Holt S, et al. Acid suppression and gastric mucosal cell biology. Dig Dis Sci 1994;39:1843-52.
46. Solcia E, Fiocca R, Villani L, et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol 1991;180(suppl):146-59.
47. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study [see comments]. Gastroenterology 1993;104:994-1006.
48. Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990;14:503-13.
49. Freston JW. Clinical significance of hypergastrinaemia: Relevance to gastrin monitoring during omeprazole therapy. Digestion 1992;51:102-14.
50. Eissele R, Brunner G, Fischer B, et al. Evaluation of enterochromaffin-like (ECL)-cell hypreplasia during long term treatment with the proton pump inhibitor lansoprazole. Gastroenterology 1993;104:A74.
51. Eissele R, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia [see comments]. Gastroenterology 1997;112:707-17.
52. Solcia E, Rindi G, Havu N, Elm G. Qualitative studies of gastric endocrine cells in patients treated long term with omeprazole. Scand J Gastroenterol 1989;166(suppl):129-37.
53. Robinson M. Review article: Current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999;13(suppl 5):5-10.